Comment from Harvard Medical School

Summary: Dr. Alan M. Altman, an Assistant Clinical Professor at Harvard Medical School, opposes the FDA's decision to withdraw the NDAs for estrogen/androgen combination drugs. He argues that these medications are essential for treating a well-documented patient population, particularly women with surgical menopause or those who do not respond to traditional hormone replacement therapy.